Physician profile
Pradeep Garg
NPI 1952376469
$8,241.26
in general payments reported to CMS, 2019-2025
35 companies · $936 in 2025
The $936 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,762 · 2020: $286 · 2021: $1,525 · 2022: $1,248 · 2023: $1,335 · 2024: $1,148 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,419.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,093.21 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,056.38 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $991.65 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $798.93 | 2021-2025 | |
| Amgen INC. | $519.42 | 2021-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $511.69 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $429.57 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $404.58 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $367.27 | 2019-2022 | |
| Pfizer INC. | $265.56 | 2019-2025 | |
| Allergan, INC. | $226.08 | 2019 | |
| Astellas Pharma US INC | $207.58 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $173.75 | 2019-2024 | |
| Amarin Pharma, INC. | $164.94 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $144.97 | 2023-2024 | Gemtesa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $97.95 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $91.91 | 2019-2023 | |
| Indivior INC. | $70.24 | 2019-2024 | Sublocade |
| Eisai INC. | $69.29 | 2021 | |
| Abbott Laboratories | $66.88 | 2021-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $58.81 | 2019-2022 | |
| Horizon Therapeutics Plc | $56.66 | 2019-2022 | |
| Optinose US, INC. | $54.67 | 2024 | |
| Orexo US, INC. | $49.15 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $46.28 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $37.60 | 2021 | |
| Esperion Therapeutics, INC. | $27.94 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.13 | 2019 | |
| Axsome Therapeutics, INC. | $27.01 | 2023 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $19.68 | 2019 | |
| Circassia INC. | $18.98 | 2020 | |
| Nabriva Therapeutics, Plc | $17.19 | 2021 | |
| Sanofi Pasteur INC. | $16.69 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.24 | 2019 | |
| Collegium Pharmaceutical, INC. | $15.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradeep Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.